- Home
- NTRB vs GANX Comparison
NTRB vs GANX Comparison
Compare NTRB & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTRB | GANX |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.6M | 76.8M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NTRB | GANX |
|---|---|---|
| Price | $6.59 | $1.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | 120.0K | ★ 430.2K |
| Earning Date | 09-04-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.46 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,036,651.00 | $55,180.00 |
| Revenue This Year | $4,584.65 | N/A |
| Revenue Next Year | $89.09 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.80 | $1.53 |
| 52 Week High | $9.19 | $4.34 |
Technical Indicators
Market Signals| Indicator | NTRB | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 49.68 | 27.37 |
| Support Level | $6.56 | N/A |
| Resistance Level | $9.19 | $2.01 |
| Average True Range (ATR) | 0.89 | 0.10 |
| MACD | -0.29 | -0.02 |
| Stochastic Oscillator | 25.10 | 2.16 |
Price Performance
Historical ComparisonAbout NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.